An article in the health section of the Wall Street Journal says that the FDA has approved an Alzheimer’s test developed by Eli Lilly & Co.
“The much-anticipated tool detects the presence of proteins in the brain that are related to Alzheimer’s disease enabling clinicians to detect Alzheimer’s earlier and more accurately in patients at the earliest sign of memory problems—a potential boon to treatment and developing drugs against the disease.
The test uses a chemical called florbetapir, known by the brand name Amyvid which is a radioactive agent that tags clumps of a sticky substance called an amyloid. Amyloid proteins are hallmarks of Alzheimer’s disease. The chemical, which costs $1,600 per dose, then is detected using a brain imaging technique called positron emission tomography, known as PET scans.”